Order Article Reprints

Hosseini I, Fleisher B, Getz J, Decalf J, Kwong M, Ovacik M, Bainbridge TW, Moussion C, Rao GK, Gadkar K, et al. A Minimal PBPK/PD Model with Expansion-Enhanced Target-Mediated Drug Disposition to Support a First-in-Human Clinical Study Design for a FLT3L-Fc Molecule. Pharmaceutics. 2024; 16(5):660. https://doi.org/10.3390/pharmaceutics16050660

Hosseini, Iraj, Brett Fleisher, Jennifer Getz, Jérémie Decalf, Mandy Kwong, Meric Ovacik, Travis W. Bainbridge, Christine Moussion, Gautham K. Rao, Kapil Gadkar, and et al. 2024. "A Minimal PBPK/PD Model with Expansion-Enhanced Target-Mediated Drug Disposition to Support a First-in-Human Clinical Study Design for a FLT3L-Fc Molecule" Pharmaceutics 16, no. 5: 660. https://doi.org/10.3390/pharmaceutics16050660

Hosseini, I., Fleisher, B., Getz, J., Decalf, J., Kwong, M., Ovacik, M., Bainbridge, T. W., Moussion, C., Rao, G. K., Gadkar, K., Kamath, A. V., & Ramanujan, S. (2024). A Minimal PBPK/PD Model with Expansion-Enhanced Target-Mediated Drug Disposition to Support a First-in-Human Clinical Study Design for a FLT3L-Fc Molecule. Pharmaceutics, 16(5), 660. https://doi.org/10.3390/pharmaceutics16050660